{"id":203242,"date":"2025-11-27T15:56:13","date_gmt":"2025-11-27T15:56:13","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/203242\/"},"modified":"2025-11-27T15:56:13","modified_gmt":"2025-11-27T15:56:13","slug":"freya-pharma-solutions-rebrands-as-arletta-pharma","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/203242\/","title":{"rendered":"Freya Pharma Solutions Rebrands as Arletta Pharma"},"content":{"rendered":"<ul>\n<li style=\"margin-top:0cm; margin-bottom:0cm;\"><strong><b>New name reflects company\u2019s transformation as it advances toward the final phase of Lybrido\u2122\u2019s clinical development <\/b><\/strong><\/li>\n<li style=\"margin-top:0cm; margin-bottom:0cm;\"><strong><b>The Arletta butterfly symbolism underscores commitment to women\u2019s health and lifecycle transitions <\/b><\/strong><\/li>\n<li style=\"margin-top:0cm; margin-bottom:0cm;\"><strong><b>CDU Phase II study ongoing with preliminary data expected near-term; ALETTA pivotal study positioned for launch pending financing completion<\/b><\/strong><\/li>\n<li style=\"margin-top:0cm; margin-bottom:0cm;\"><strong><b>Company leverages fifteen years of research in Female Sexual Disorders<\/b><\/strong><\/li>\n<\/ul>\n<p align=\"justify\"><strong>Amsterdam, the Netherlands, 27 November 2025<\/strong> &#8211; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NDrdw5xssrhvz_I7fxIX7DQ1UtLKsihPJCU1ZKPPDaISj3kkLqB8IVb_wv3PDFftjhVmdya8z8y5gEOvSO88nZf4WehP_red7Gp9TSabGK9gHHvhFCmcK_N2JmCXbGmq\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\">Freya Pharma Solutions<\/a>, Freya Pharma Solutions, a pharmaceutical company specializing in innovative therapies for women diagnosed with Female Sexual Disorders (FSD), today announced it will rebrand as <strong>Arletta Pharma Solutions<\/strong>, effective December 1, 2025. The new name, derived from a rare butterfly species, symbolizes the company\u2019s transformation as it progresses toward pivotal clinical milestones and its strategic objectives of securing regulatory approval.<\/p>\n<p align=\"justify\">\u201cLike a caterpillar emerging as a butterfly, this name change marks the beginning of our company\u2019s final phase,\u201d <strong>said CEO Nicole Hijnen, Chief Executive Officer of Arletta Pharma Solutions.<\/strong> \u201cThis rebranding comes at the optimal moment in our evolution\u2014as we advance our clinical programs and prepare to deliver on our founding mission to address a significant unmet medical need affecting millions of women worldwide.\u201d<\/p>\n<p align=\"justify\"><strong>The Butterfly: A Universal Symbol in Women\u2019s Healthcare<\/strong><br \/>The name Arletta, inspired by a rare butterfly species, carries profound significance for women\u2019s medical care. The butterfly symbolizes transformation, change, beauty, and freedom\u2014concepts that resonate deeply throughout women\u2019s healthcare. Internationally, the term \u201cbutterfly\u201d appears frequently in medical contexts related to women\u2019s health, from anatomical structures to diagnostic indicators, reflecting the transformative nature of women\u2019s life stages.<\/p>\n<p align=\"justify\">Throughout their lives, women undergo remarkable transformations\u2014puberty, reproductive years, perimenopause, and postmenopause\u2014each representing a metamorphosis that requires specialized medical attention and understanding. Arletta Pharma\u2019s focus on developing innovative therapies for Female Sexual Interest\/Arousal Disorder (FSIAD) acknowledges these unique transitions and the need for targeted therapeutic solutions that respect the complexity of female sexual health.<\/p>\n<p align=\"justify\"><strong>Clinical Programs Advancing<\/strong> <br \/>Arletta Pharma\u2019s Clitoral Doppler Duplex Ultrasonography (CDU) Phase II study is currently ongoing at Chaim Sheba Medical Center, evaluating two testosterone-sildenafil dose-combinations in 16 premenopausal women with acquired generalized FSIAD. Led by Prof. Cobi Reisman and Dr. Anna Padoa, the study utilizes clitoral doppler duplex ultrasound imaging to quantify clitoral blood flow parameters, with preliminary data expected in the near term. Additionally, the company is finalizing preparations for the ALETTA pivotal study across 20 European research sites in five countries, with enrollment positioned to commence in the foreseeable future pending completion of financing arrangements\u2014a critical milestone toward regulatory approval in Europe.<\/p>\n<p align=\"justify\"><strong>Building on Fifteen Years of Scientific Foundation<\/strong> <br \/>Arletta Pharma Solutions (formerly Freya Pharma Solutions) is developing Lybrido\u2122, an innovative on-demand dual-action therapy for FSIAD and Hypoactive Sexual Desire Disorder (HSDD), building upon fifteen years of research. Lybrido\u2122 features a novel dual-route, dual-release tablet with a testosterone coating for sublingual administration and a sildenafil (PDE-5 inhibitor) inner core. The delayed-immediate-release matrix synchronizes peak plasma concentration of sildenafil with the testosterone-induced window of increased sexual motivation, enhancing genital arousal through increased responsivity to sexual stimuli. Effects last 3 to 6 hours after intake. To date, Lybrido\u2122 has been investigated in 20 Phase I and Phase IIa trials, plus large-scale Phase IIb trials across 17 US research sites.<\/p>\n<p align=\"justify\"><strong>About Female Sexual Disorders<\/strong> <br \/>Low sexual desire is the most common female sexual disorder (FSD), often causing clinically significant distress, dissatisfaction in intimate relationships, and profoundly impacting emotional well-being. Female Sexual Interest\/Arousal Disorder (FSIAD), as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), combines persistent reductions in sexual interest and\/or arousal lasting six months while causing clinically significant distress. FSIAD represents the clustering of Hypoactive Sexual Desire Disorder and Female Sexual Arousal Disorder, listed in the World Health Organization\u2019s International Classification of Diseases, 11th Revision (ICD-11) under Code HA00\/HA01.0.<\/p>\n<p align=\"justify\"><strong>About Arletta Pharma Solutions<\/strong> <br \/>Arletta Pharma Solutions (formerly Freya Pharma Solutions) is a pharmaceutical company focused on developing effective pharmaceutical therapies for FSIAD\/HSDD, building upon fifteen years of solid research. The company\u2019s core asset under development is Lybrido\u2122, designed to address FSIAD\/HSDD through an innovative on-demand dual-action mechanism. Based in Amsterdam, The Netherlands, Arletta Pharma Solutions aims to offer patients a convenient, personalized on-demand solution for this recognized unmet medical need. <\/p>\n<p>For further information please contact: <\/p>\n<p><b>Arletta<\/b><b> Pharma <\/b><b>Solutions<\/b><b>, Amsterdam <\/b><br \/>Marcel Wijma, Chief Business Officer\u00a0<br \/>marcel@arlettapharmasolutions.com<\/p>\n<p><b>For media <\/b><br \/>LifeSpring Life Sciences Communication, Amsterdam<br \/>Leon Melens <br \/>T: +31 6 538 16 427<br \/>E: lmelens@lifespring.nl <\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=YuUCsuGcyVg7sfElHOTzTapQsWuvzXBH4vVLAldLe6q3Xo9p89VaeH4OgCD2PRZJBxlrdzBNoiRgvP9QBULAwuJPyqWtK3TOxH69vMG3LAPIpI8cF31JvnuoYM_uBn6JXwuDV4X8SgUHuVS4A7PGXZNLaLmySZ1QDtWImEVuxNmx3j6gd4z_YKef05f92gp10s1sULFMhWpGsVZ_0BB5XbvnU9vi9pXtcBnUt_Tu6k8=\" title=\"Freya Pharma Press Release Rebranding in Arletta_final\" rel=\"nofollow noopener\">Freya Pharma Press Release Rebranding in Arletta_final<\/a>\n      <\/li>\n<\/ul>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2025\/11\/Arletta-Pharma-Solutions.png\" referrerpolicy=\"no-referrer-when-downgrade\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"New name reflects company\u2019s transformation as it advances toward the final phase of Lybrido\u2122\u2019s clinical development The Arletta&hellip;\n","protected":false},"author":2,"featured_media":203243,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[78],"tags":[111906,10723,111907,18,111908,135,19,17,9222,577,12000],"class_list":{"0":"post-203242","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-arletta-pharma-solutions","9":"tag-clinical-trials","10":"tag-corporate-announcement","11":"tag-eire","12":"tag-female-sexual-disorders","13":"tag-health","14":"tag-ie","15":"tag-ireland","16":"tag-pharmaceutical","17":"tag-sexual-health","18":"tag-womens-health"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/115622483661541255","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/203242","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=203242"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/203242\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/203243"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=203242"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=203242"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=203242"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}